On February 26, 2020 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported a number of presentations at investor, pharmaceutical industry and scientific conferences in Europe and the U.S. in the coming months (Press release, NicOx, FEB 26, 2020, View Source [SID1234554774]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
INVESTOR AND PHARMACEUTICAL INDUSTRY CONFERENCES
Members of Nicox’s management team will participate and be available for one-on-one meetings at the following conferences:
Oppenheimer 30th Annual Healthcare Conference, March 17-18, New York, U.S.
H.C. Wainwright Global Life Sciences Conference, April 19-21, London, U.K.
BIO 2020, June 8-11, San Diego, U.S.
SCIENTIFIC CONFERENCES
Presentations at major ophthalmology conferences including American Glaucoma Society (AGS), Association for Research in Vision and Ophthalmology (ARVO) and American Society of Cataract and Refractive Surgery (ASCRS).
Details of the presentations (all U.S. local times):
AGS 2020 Annual Meeting – February 27 – March 1, 2020, Washington, U.S.
Title: NCX 470, a nitric oxide-donating bimatoprost analog, demonstrates superiority to latanoprost in Phase 2 Dolomites clinical trial (podium presentation)
Date: February 29, 2020 from 12:03 PM to 12:10 PM
Presenter: Dr. David Wirta, MD, Aesthetic Eye Care Institute, CA, U.S.
ARVO 2020 Annual Meeting – May 3-7, 2020, Baltimore, U.S.
Title: NCX 470 for IOP lowering: results of the Phase 2 Dolomites trial (poster presentation)
Date: May 6, 2020 from 10:15 AM to 12:00 PM
Presenter: Dr. Thomas Walters, MD, Keystone Research Center, PA, U.S.
Title: Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma (paper presentation)
Date: May 5, 2020 from 12:45 PM to 1:00 PM
Presenter: Francesco Impagnatiello, PhD, Nicox Research Institute
Title: Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma (poster presentation)
Date: May 4, 2020 from 8:15 AM to 10:00 AM
Presenter: Elena Bastia, PhD, Nicox Research Institute
ASCRS 2020 – May 15-19, 2020, Boston, U.S.
Title: Prospective study of NCX 470 for IOP lowering: Phase 2 clinical results (poster presentation)
Date: May 15-19
Presenter: Dr. Thomas Walters, MD, Keystone Research Center, PA, U.S.
Title: Prospective study of NCX 4251 (fluticasone propionate nanocrystals ophthalmic suspension, 0.1%) for treatment of blepharitis (poster presentation)
Date: May 15-19
Presenter: Dr. Gary Foulks, MD, University of Louisville Department of Ophthalmology and Vision Science, KY, U.S.